Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Péneau C, Imbeaud S, La Bella T, et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut. 2022;71(3):616–626. doi:10.1136/gutjnl-2020-323153
   PubMed Web of Science ®Google Scholar
• Xu L, Gao H, Huang J, et al. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol. 2015;30(6):1032–1039. doi:10.1111/jgh.12910
   PubMed Web of Science ®Google Scholar
• Huang G, Lau WY, Wang ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg. 2015;261(1):56–66. doi:10.1097/SLA.0000000000000858
   PubMed Web of Science ®Google Scholar
• Huang G, Li PP, Lau WY, et al. Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial. Ann Surg. 2018;268(6):943–954. doi:10.1097/SLA.0000000000002727
   PubMed Web of Science ®Google Scholar
• Huang S, Xia Y, Lei Z, et al. Antiviral therapy inhibits viral reactivation and improves survival after repeat hepatectomy for hepatitis b virus-related recurrent hepatocellular carcinoma. J Am Coll Surg. 2017;224(3):283–293 e4. doi:10.1016/j.jamcollsurg.2016.11.009
   PubMed Web of Science ®Google Scholar
• Jang JW, Yoo SH, Nam HC, et al. Association of prophylactic anti-hepatitis B virus therapy with improved long-term survival in patients with hepatocellular carcinoma undergoing transarterial therapy. Clin Infect Dis. 2020;71(3):546–555. doi:10.1093/cid/ciz860
   PubMed Web of Science ®Google Scholar
• Lao XM, Luo G, Ye LT, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int Apr. 2013;33(4):595–604. doi:10.1111/liv.12112
   PubMed Web of Science ®Google Scholar
• Lee IC, Lee PC, Chao Y, et al. Application and impact of antiviral therapy for patients with HBV-related hepatocellular carcinoma receiving sorafenib and lenvatinib treatment. Viruses. 2022;14(11):2355. doi:10.3390/v14112355
   PubMed Web of Science ®Google Scholar
• Lyu N, Wang X, Li JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III Trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468–480. doi:10.1200/JCO.21.01963
   PubMed Web of Science ®Google Scholar
• Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40(2):150–160. doi:10.1200/JCO.21.00608
   PubMed Web of Science ®Google Scholar
• He M, Li Q, Zou R, et al. sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953–960. doi:10.1001/jamaoncol.2019.0250
   PubMed Web of Science ®Google Scholar
• Mei J, Tang YH, Wei W, et al. Hepatic arterial infusion chemotherapy combined With PD-1 Inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma. Front Oncol. 2021;11:618206. doi:10.3389/fonc.2021.618206
   PubMed Web of Science ®Google Scholar
• Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018;69(1):60–69. doi:10.1016/j.jhep.2018.02.008
   PubMed Web of Science ®Google Scholar
• Liu S, Lai J, Lyu N, et al. Effects of antiviral therapy on HBV reactivation and survival in hepatocellular carcinoma patients undergoing hepatic artery infusion chemotherapy. Front Oncol. 2021;2021:10.
   Google Scholar
• Lampertico P, Agarwal K, Berg T; European Association for the Study of the Liver. Electronic address eee, European association for the study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology Apr. 2018;67(4):1560–1599. doi:10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Choi J, Jo C, Lim YS. Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. Hepatology. 2021;73(2):661–673. doi:10.1002/hep.31289
   PubMed Web of Science ®Google Scholar
• Wang XH, Hu ZL, Fu YZ, et al. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. J Gastroenterol. 2022;57(3):185–198. doi:10.1007/s00535-022-01855-x
   PubMed Web of Science ®Google Scholar
• Hu Z, Zeng H, Hou J, et al. Tenofovir vs. entecavir on outcomes of hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation. Viruses. 2022;14(4):656. doi:10.3390/v14040656
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim BK, Park SY, et al. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. Eur J Intern Med. 2021;89:48–55. doi:10.1016/j.ejim.2021.02.019
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Lyu N, Lin Y, Kong Y, et al. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma. Gut. 2018;67(2):395–396. doi:10.1136/gutjnl-2017-314138
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-The ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• Rassen JA, Shelat AA, Myers J, et al. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(S2):69–80. doi:10.1002/pds.3263
   PubMedGoogle Scholar
• Li H, Wu Z, Chen J, et al. External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Clin Exp Med. 2022;23(5):1537–1549. doi:10.1007/s10238-022-00972-4
   PubMed Web of Science ®Google Scholar
• Li H, Su K, Guo L, et al. PD-1 inhibitors combined with antiangiogenic therapy with or without transarterial chemoembolization in the treatment of hepatocellular carcinoma: a propensity matching analysis. J Hepatocell Carcinoma. 2023;10:1257–1266. doi:10.2147/JHC.S415843
   PubMed Web of Science ®Google Scholar
• Zhang YQ. Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol Apr. 2015;21(13):3860–3866. doi:10.3748/wjg.v21.i13.3860
   PubMed Web of Science ®Google Scholar
• Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698–3715. doi:10.1200/JCO.20.01757
   PubMed Web of Science ®Google Scholar
• Sohn W, Kang TW, Choi S-K, et al. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget. 2016;7(30):47794–47807. doi:10.18632/oncotarget.10026
   PubMedGoogle Scholar
• Zhou ZG, Zheng XR, Zhou Q, et al. Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chin J Cancer. 2015;34(5):205–216. doi:10.1186/s40880-015-0017-7
   PubMedGoogle Scholar
• Cho H, Ahn H, Lee DH, et al. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals. J Viral Hepat. 2018;25(6):707–717. doi:10.1111/jvh.12855
   PubMed Web of Science ®Google Scholar
• Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–219. doi:10.1053/j.gastro.2014.10.039
   PubMed Web of Science ®Google Scholar
• Mustafayev K, Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clin Microbiol Infect. 2022;28(10):1321–1327. doi:10.1016/j.cmi.2022.02.042
   PubMed Web of Science ®Google Scholar
• Jang JW. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. World J Gastroenterol. 2014;20(24):7675. doi:10.3748/wjg.v20.i24.7675
   PubMed Web of Science ®Google Scholar
• Voican CS, Mir O, Loulergue P, et al. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol. 2016;27(12):2172–2184. doi:10.1093/annonc/mdw414
   PubMed Web of Science ®Google Scholar
• Kim HY, Yoo JJ, Oh S, et al. Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: a multicenter study. J Med Virol. 2018;90(10):1593–1603. doi:10.1002/jmv.25241
   PubMed Web of Science ®Google Scholar
• Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV. Risk of HBV reactivation during therapies for HCC: a systematic review. Hepatology. 2022;75(5):1257–1274. doi:10.1002/hep.32241
   PubMed Web of Science ®Google Scholar
• Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;370:m2200.
   PubMedGoogle Scholar
• Wang J, Zheng Z, Wu T, et al. Hepatic arterial infusion chemotherapy as a timing strategy for conversion surgery to treat hepatocellular carcinoma: a single-center real-world study. J Hepatocell Carcinoma. 2022;9:999–1010. doi:10.2147/JHC.S379326
   PubMed Web of Science ®Google Scholar
• Su K, Shen Q, Tong J, et al. Construction and validation of a nomogram for HBV-related hepatocellular carcinoma: a large, multicenter study. Ann. Hepatol. 2023;28(4):101–109. doi:10.1016/j.aohep.2023
   Web of Science ®Google Scholar
• Su K, Huang W, Li X, et al. Evaluation of lactate dehydrogenase and alkaline phosphatase as predictive biomarkers in the prognosis of hepatocellular carcinoma and development of a new nomogram. J Hepatocell Carcinoma. 2023;10:69–79. doi:10.2147/JHC.S398632
   PubMed Web of Science ®Google Scholar
• Li H, Guo L, Su K, et al. Construction and validation of TACE therapeutic efficacy by ALR score and nomogram: a large, multicenter study. J Hepatocell Carcinoma. 2023;10:1009–1017. doi:10.2147/JHC.S414926
   PubMed Web of Science ®Google Scholar
• Shen J, Qi W, Dai J, et al. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy. Chin Med J. 2021;135(3):301–308. doi:10.1097/CM9.0000000000001864
   PubMed Web of Science ®Google Scholar